Guided Clarity

Guided Clarity is a biotechnology firm specializing in innovative therapeutic solutions aimed at targeting cancer's complexities through a portfolio of therapeutic compounds designed to enhance treatment efficacy. Guided Clarity operates in the biotechnology sector, focusing on developing advanced therapeutic solutions for cancer treatment. The company was founded by Helen Chen and Olof Mollstedt. Its headquarters is located in San Francisco, US.

The most recent funding round took place on February 20, 2019, when Guided Clarity raised an undisclosed amount of Seed funding from investors SOSV and IndieBio. Guided Clarity is committed to developing innovative therapeutic solutions that address the complexities of cancer as a dynamic ecosystem. Their core product offerings include a portfolio of compounds designed to disrupt metabolic and inflammatory triggers within the tumor microenvironment, thereby collapsing tumor ecosystems. These compounds aim to address cancer drug resistance by impacting a broad range of cell types, including cancer cells and their quasi-cancerous counterparts.

The company's research is rooted in the intersections of cancer, aging, and immunity, with programs at various stages of preclinical development, primarily serving healthcare providers, research institutions, and pharmaceutical companies globally, especially in North America and Europe. Guided Clarity's revenue model revolves around partnerships and collaborations within the biotechnology sector, particularly through research and development agreements with academic institutions and pharmaceutical companies. The firm engages in B2B transactions, providing its therapeutic compounds for preclinical testing and potential clinical trials, enabling biotech firms to enhance their cancer treatment pipelines. While specific pricing details are not disclosed, the revenue structure typically involves milestone payments associated with research and development progress, along with potential licensing agreements depending on clinical success.

Guided Clarity plans to expand its product offerings with new therapeutic solutions for cancer, focusing on innovative compounds designed to enhance treatment effectiveness. They are targeting growth in North America and Europe and aim to penetrate new markets by leveraging the Seed funding raised in February 2019. This funding will support ongoing research and development initiatives, which will facilitate the progression of their therapeutic candidates through preclinical stages and into clinical trials.